Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy

Hypopituitarism Clinical Trial

Official title:

Next Day Early Morning Growth Hormone as Predictor of Pituitary Function After Transsphenoidal Adenomectomy

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03708523
• Other study ID #: 201809035RIND
• Status: Not yet recruiting
• Start date: November 1, 2018
• Est. completion date: September 2019

Study information

• Verified date: October 2018
• Source: National Taiwan University Hospital
• Contact: Fon-Yih Tsuang
• Phone: 0972651142
• Email: tsuangfy[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study tried to highlight the predictive value of the morning postoperative cortisol levels, which can act as the prognosis value of the postoperative pituitary function, providing future medication advices for improving patients' safety of drugs.

Description:

Transsphenoidal adenomectomy usually accompanied by the failure or recovery of the pituitary gland, which usually causing further hypopituitarism and hormone recovery. In order to prevent the potential applications of adrenal cortical malfunction after the surgery, many medical centers will use glucocorticoid supplements during the perioperative period care. However, this treatment might expose the normal hypothalamic-pituitary-adrenal (HPA) axis function patients into potential threats after the treatment of glucocorticoid supplements, such as bone loss, hypertension, emotional distress, and weight gain. To avoid unnecessary supply of glucocorticoids, the key question is to monitor the pituitary function. Thus, in this study we try to predict the morning postoperative cortisol levels, for further prediction of the postoperative pituitary function. To do so, we will review the retrospective charts of transsphenoidal adenomectomied patients from January, 2013 to April, 2018 in the NTUH Taipei. Use statistical methods analyzing all sorts of medical reports, including perioperative hormone thresholds.This study tried to highlight the predictive value of the morning postoperative cortisol levels, which can act as the prognosis value of the postoperative pituitary function, providing future medication advices for improving patients' safety of drugs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: September 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion:

Patients who had been treated with TSA were enrolled.

Exclusion:

1. Hypopituitarism preoperatively.

2. Acromegaly

3. Multiple operations

4. Incomplete hormone data or loss of follow-up

Related Conditions & MeSH terms

• Hypopituitarism
• Pituitary Diseases

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei city

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Next Day Early Morning Growth Hormone as Predictor of Pituitary Function After Transsphenoidal Adenomectomy	To predict the morning postoperative cortisol levels, for further prediction of the postoperative pituitary function.	2 days